Menu
GWAS Study

Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.

Jiang Y, Meyers TJ, Emeka AA et al.

34993496 PubMed ID
GWAS Study Type
6361 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

JY
Jiang Y
MT
Meyers TJ
EA
Emeka AA
CL
Cooley LF
CP
Cooper PR
LN
Lancki N
HI
Helenowski I
KL
Kachuri L
LD
Lin DW
SJ
Stanford JL
NL
Newcomb LF
KS
Kolb S
FA
Finelli A
FN
Fleshner NE
KM
Komisarenko M
EJ
Eastham JA
EB
Ehdaie B
BN
Benfante N
LC
Logothetis CJ
GJ
Gregg JR
PC
Perez CA
GS
Garza S
KJ
Kim J
ML
Marks LS
DM
Delfin M
BD
Barsa D
VD
Vesprini D
KL
Klotz LH
LA
Loblaw A
MA
Mamedov A
GS
Goldenberg SL
HC
Higano CS
SM
Spillane M
WE
Wu E
CH
Carter HB
PC
Pavlovich CP
MM
Mamawala M
LT
Landis T
CP
Carroll PR
CJ
Chan JM
CM
Cooperberg MR
CJ
Cowan JE
MT
Morgan TM
SJ
Siddiqui J
MR
Martin R
KE
Klein EA
BK
Brittain K
GP
Gotwald P
BD
Barocas DA
DJ
Dallmer JR
GJ
Gordetsky JB
SP
Steele P
KS
Kundu SD
SJ
Stockdale J
RM
Roobol MJ
VL
Venderbos LDF
SM
Sanda MG
AR
Arnold R
PD
Patil D
EC
Evans CP
DM
Dall'Era MA
VA
Vij A
CA
Costello AJ
CK
Chow K
CN
Corcoran NM
RS
Rais-Bahrami S
PC
Phares C
SD
Scherr DS
FT
Flynn T
KR
Karnes RJ
KM
Koch M
DC
Dhondt CR
NJ
Nelson JB
MD
McBride D
CM
Cookson MS
SK
Stratton KL
FS
Farriester S
HE
Hemken E
SW
Stadler WM
PT
Pera T
BD
Banionyte D
BF
Bianco FJ
LI
Lopez IH
LS
Loeb S
TS
Taneja SS
BN
Byrne N
AC
Amling CL
MA
Martinez A
BL
Boileau L
GF
Gaylis FD
PJ
Petkewicz J
KN
Kirwen N
HB
Helfand BT
XJ
Xu J
SD
Scholtens DM
CW
Catalona WJ
WJ
Witte JS
Chapter II

Abstract

Summary of the research findings

Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 5,222 PC patients and 1,139 other patients from replication cohorts, all of whom initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 variants associated with conversion, 15 of which were not previously associated with PC risk. With a transcriptome-wide association study (TWAS), we found two genes associated with conversion (MAST3, p = 6.9×10-7 and GAB2, p = 2.0×10-6). Moreover, increasing values of a previously validated 269-variant genetic risk score (GRS) for PC was positively associated with conversion (e.g., comparing the highest to the two middle deciles gave a hazard ratio [HR] = 1.13; 95% Confidence Interval [CI]= 0.94-1.36); whereas, decreasing values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95% CI, 1.04-1.50). These results suggest that germline genetics may help inform and individualize the decision of AS-or the intensity of monitoring on AS-versus treatment for the initial management of patients with low-risk PC.

1,609 European ancestry cases, 3,613 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

6361
Total Participants
GWAS
Study Type
Yes
Replicated
77 European ancestry cases, 348 European ancestry controls, 123 African ancestry cases, 273 African ancestry controls, 88 Asian ancestry cases, 149 Asian ancestry controls, 21 Latin American cases, 60 Latin American controls
Replication Participants
European, African unspecified, Asian unspecified, Hispanic or Latin American
Ancestry
Canada, Netherlands, U.S., Australia
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.